ClinicalTrials.gg
Not yet recruitingNCT06710899Updated Feb 11, 2026

Vitamin C and Hiprex in rUTI

An Early Phase 1 interventional study of Methenamine Hippurate 1g BD and Methenamine Hippurate 1g BD + Vitamin C 1g BD in Urinary Tract Infections, sponsored by University Hospitals of North Midlands NHS Trust. Not yet recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by University Hospitals of North Midlands NHS Trust · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.

Planned enrollment
14th of 17
20 · median 48
Started
2027
the only one that year
Phase 1
5 of 31
1 open now
Registered
27th of 31
by date

Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 5 in phase 1, and was the 27th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Urinary Tract Infections with a site in United Kingdom, or all of them as a file.
02

Study summary

A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

03

Conditions studied

  • Urinary Tract Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Age ≥18 years
  • Recurrent proven UTI, defined as "two or more proven infections in six months or three or more infections in six months"
  • Willing and able to give fully
  • Patients suitable for prophylaxis following discussion with their clinician.
  • No to treatment with methenamine hippurate or Vitamin C
  • All women will have undergone standard diagnostic work-up and have followed routine conservative UTI prevention measures.
  • A working email address to be used to submit urine pH results
  • Willing and able to comply with the study procedures
  • Females of must be willing to use a highly effective method of (hormonal or barrier method of birth control; abstinence; sterilisation or vasectomised partner)

Exclusion criteria

Exclusion Criteria:

  • Males
  • Women who are pregnant or breast-feeding
  • to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, less than 10 ml/min, severe hepatic impairment
  • Currently using vitamin C containing supplement or cranberry extract tablets
  • Women using urinary alkalinisation agents, e.g potassium citrate, sodium bicarbonate
  • Currently receiving any form of bladder instillation or intradetrusor Onabotulinum Toxin A injections
  • Patients already on low-dose antibiotics or methenamine hippurate (due to delay that will be incurred by 3-month )
  • Indwelling urinary catheter in situ or performing clean intermittent self-catheterisation
  • Correctable urinary tract abnormalities, e.g., urinary tract calculi, urinary retention
  • Formation of ileal conduit or augmented bladder
  • Neurogenic bladder dysfunction
  • Hyperoxaluria
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment phase A

    Methenamine Hippurate 1g BD for 6 months

    Drug: Methenamine Hippurate 1g BD

  • Experimental
    Treatment phase B

    Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months

    Drug: Methenamine Hippurate 1g BD + Vitamin C 1g BD

  • Experimental
    Treatment phase C

    Methenamine 1g BD for 6 months

    Drug: Methenamine Hippurate 1g BD

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of UTIs

    The incidence of symptomatic UTI during each six-month treatment phase of either methenamine hippurate alone or methenamine hippurate plus vitamin C

    Time frame: 24 months

Secondary outcomes

  1. Urine pH

    Measurement of urine pH during each treatment phase

    Time frame: 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2027, 7 months later.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartEst.
Jan 2027
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06710899
Lead sponsor
University Hospitals of North Midlands NHS Trust
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Jan 2027 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 11, 2026

Study contacts

Aviva Ogbolosingha
Contact
aviva.ogbolosingha@uhnm.nhs.uk
01782 675380

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methenamine hippurate

Start the discussion